Therapeutic consequences of MRD after 2 cycles of treatment, at the end of treatment, and during follow-up for the genetic subgroups defined by ELN. abn, abnormality; AZA, azacitidine; BM, bone marrow; bZIP inframe, inframe mutations in the bZIP domain; chemo, consolidation chemotherapy; del, deletion; HMA, hypomethylating agent; maint, maintenance; MRD−, MRD negative; MRD+, MRD positive; mut, mutated; TKD, tyrosine kinase domain; wt, wild type. ¹Chemotherapy consolidation plus FLT3i may be considered in patients with low FLT3-ITD allelic ratio with NPM1 comutation. ²If alloHCT is contraindicated. ³With or without salvage treatment prior to alloHCT/DLI.